Acadia Pharmaceuticals | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
ALKERMES USD 2.06B 99.72M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Corcept Therapeutics USD 840.55M 56.3M 2024-12
Cytokinetics USD 1.4B 34.39M 2024-12
Eisai JPY 1.43T 111.45B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Incyte USD 5.44B 431.89M 2024-12
Intra Cellular Therapies USD 1.37B 42.47M 2024-12
J&J USD 180.1B 1.82B 2024-12
Moderna USD 14.14B 1.66B 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Prothena USD 547.11M 48.15M 2024-12
PTC Therapeutics USD 1.71B 137.21M 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Acadia Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.